Medicines – Non-exclusive rebate agreement for peginterferon alfa-2a for the period 01/08/2026 to 31/07/2028

Summary

The tender concerns a non-exclusive rebate agreement for medicines containing the active substance peginterferon alfa-2a for the period 01/08/2026 to 31/07/2028. DAK-Gesundheit intends to conclude medicine rebate agreements with as many interested pharmaceutical companies as possible for the medicines named by the bidder in Annex 2 to the contract. This is an open procedure for supplies. The machine-readable notice did not include precise exclusion grounds or qualification requirements; these must be checked in the tender documents.